National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

  • Alectinib (Alecensa®) - January 15, 2019

    Following assessment of the applicant’s submission the NCPE recommends that alectinib (Alecensa®), for the first line treatment of adult patients with ALK-positive advanced NSCLC, not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013

  • Lesinurad (Zurampic®) - December 6, 2018

    The NCPE recommends that lesinurad not be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Dinutuximab beta (Qarziba®) - October 22, 2018

    Following assessment of the applicant’s submission, the NCPE recommends that dinutuximab beta (Qarziba®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.

  • Avelumab (Bavencio®) - October 9, 2018

    The NCPE recommends that avelumab (Bavencio®) for the treatment of metastatic Merkel Cell Carcinoma not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.

  • Ocrelizumab (Ocrevus®) for PPMS - October 9, 2018

    The NCPE recommends that ocrelizumab (Ocrevus®) not be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Atezolizumab (Tecentriq®) - September 25, 2018

    The NCPE recommends that atezolizumab not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Inotuzumab ozogamicin (Besponsa®) - September 14, 2018

    The NCPE recommends that inotuzumab should be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Nivolumab (Opdivo®) for urothelial carcinoma - September 13, 2018

    The NCPE recommends that nivolumab (Opdivo®) not be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Tolvaptan (Jinarc®) - September 13, 2018

    The NCPE recommends that tolvaptan not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Goods) Act 2013.

  • Idebenone (Raxone®) - August 30, 2018

    The NCPE recommends that idebenone not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.